Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000092980

Apexbio Technology LLC ASP3026 1097917-15-1 200mg
SDP

Catalog No. 5000092980
Encompass_Preferred

ASP3026 (CAS 1097917-15-1) is a selective inhibitor of anaplastic lymphoma kinase (ALK) exhibiting an IC50 of 3 5 nM for ALK enzymatic inhibition When evaluated across a panel of 86 tyrosine kinases ASP3026 demonstrated highest selectivity for ALK ROS and ACK kinases In cellular studies ASP3026 inhibited the proliferation of EML4-ALK-expressing NCI-H2228 non-small cell lung cancer (NSCLC) cells (IC50 64 8 nM) and reduced viability in NPM-ALK anaplastic large cell lymphoma (ALCL) lines with IC50 values ranging from 0 4 to 2 5 M In vivo oral administration of ASP3026 in mouse xenograft models suppressed ALK phosphorylation and significantly reduced tumor growth ASP3026 serves as a valuable tool for investigating ALK-driven oncogenesis and for preclinical evaluation of ALK-targeted therapies

Catalog No. 50-000-92980 Supplier Apexbio Technology LLC Supplier No. A3193200
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

ASP3026 (CAS 1097917-15-1) is a selective inhibitor of anaplastic lymphoma kinase (ALK) exhibiting an IC50 of 3 5 nM for ALK enzymatic inhibition When evaluated across a panel of 86 tyrosine kinases ASP3026 demonstrated highest selectivity for ALK ROS and ACK kinases In cellular studies ASP3026 inhibited the proliferation of EML4-ALK-expressing NCI-H2228 non-small cell lung cancer (NSCLC) cells (IC50 64 8 nM) and reduced viability in NPM-ALK anaplastic large cell lymphoma (ALCL) lines with IC50 values ranging from 0 4 to 2 5 M In vivo oral administration of ASP3026 in mouse xenograft models suppressed ALK phosphorylation and significantly reduced tumor growth ASP3026 serves as a valuable tool for investigating ALK-driven oncogenesis and for preclinical evaluation of ALK-targeted therapies

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.